Belsomra (Suvorexant) FDA Approval History

How Suvorexant Works: A New Mechanism for Insomnia

Suvorexant blocks both orexin receptor subtypes (OX1R and OX2R), suppressing the wake-promoting neuropeptide signaling that keeps the brain alert. This mechanism represented a departure from the GABA-based approach used by benzodiazepines and Z-drugs. Rather than broadly sedating the central nervous system, orexin receptor antagonism narrows its effect to the arousal circuits that the hypothalamic orexin neurons drive.

The orexin system was first characterized in 1998 by two independent research groups, and early animal studies showed that orexin-deficient mice exhibited narcolepsy-like phenotypes 1. Merck began developing suvorexant (MK-4305) around 2007, advancing it through phase 1 dose-ranging trials that established proof of concept in healthy volunteers. By 2009, the compound had entered phase 2 studies confirming dose-dependent improvements in both sleep onset latency and wake after sleep onset. The FDA granted suvorexant a priority review pathway based on its novel mechanism, recognizing that no orexin-targeting insomnia drug had reached the U.S. market 2.

Phase 1 pharmacokinetic data showed a half-life of approximately 12 hours, which later became a focal point during the advisory committee review. The prolonged duration of action raised questions about residual next-morning effects, particularly at the 30 mg and 40 mg doses that Merck had originally proposed for approval.

The Phase 3 Clinical Trials That Supported Approval

Two key phase 3 randomized, double-blind, placebo-controlled trials formed the basis of the Belsomra new drug application. Herring et al. published the combined results in The Lancet Neurology in 2014 3. Trial 1 (Study 028, N=1,021) and Trial 2 (Study 029, N=1,009) enrolled adults aged 18 and older with primary insomnia as defined by DSM-IV-TR criteria.

Both trials lasted three months, with a one-month randomized withdrawal period. Patients received suvorexant at doses of 20 mg or 40 mg (for those under 65) or 15 mg or 30 mg (for those 65 and older) versus placebo. The primary endpoints were subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) measured by patient sleep diaries.

Results were consistent across both studies. In Study 028, suvorexant at the higher dose improved sTST by a mean of 25 minutes versus placebo at month 1 (P<0.001) 3. Study 029 showed a 20-minute sTST improvement at the lower dose versus placebo at month 3 (P<0.001) 3. A separate polysomnography substudy confirmed objective improvements: suvorexant reduced wake after sleep onset by approximately 22 minutes compared to placebo at one month.

A third supportive trial (Study 006) used polysomnography in 362 patients over four weeks and confirmed dose-dependent reductions in both latency to persistent sleep and wake after sleep onset. The safety database across all three trials included more than 3,291 suvorexant-treated patients 2.

The Advisory Committee Meeting: A Contentious 11-to-7 Vote

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee met on May 22, 2013 to review the suvorexant NDA. The session was notable for its sharp disagreement over dosing. Merck had submitted data supporting approval of four dose strengths: 10 mg, 20 mg, 30 mg, and 40 mg. FDA reviewers pushed back.

The committee voted 11 to 7 in favor of approval, but with a critical caveat. Multiple members expressed concern about next-day impairment at the 30 mg and 40 mg dose levels 4. Dr. Ronald Farkas, an FDA medical officer, presented driving simulation data showing that 20 mg suvorexant did not significantly impair next-morning performance, while the 40 mg dose produced effects similar to having a blood alcohol concentration above 0.05%.

"The efficacy was clearly demonstrated. The question is whether the risk-benefit at the higher doses is acceptable," said Dr. Farkas during the committee proceedings. Several committee members recommended approving only the 10 mg and 20 mg doses, while others argued the 15 mg dose would be appropriate for elderly patients who metabolize the drug more slowly.

This was not a minor regulatory disagreement. Merck's key trials had studied the 30 mg and 40 mg doses as the primary strengths. The company found itself in the unusual position of having its most-studied doses excluded from the final approved label.

FDA Approval: August 13, 2014

The FDA approved Belsomra on August 13, 2014 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance 4. The agency authorized four tablet strengths (5 mg, 10 mg, 15 mg, and 20 mg) but set the maximum recommended dose at 20 mg once nightly.

"Belsomra provides an alternative to currently available therapies for sleep disorders," said Dr. Ellis Unger, then acting director of the Office of Drug Evaluation I at the FDA's Center for Drug Evaluation and Research, in the agency's approval announcement 4. The recommended starting dose was set at 10 mg, taken no more than once per night, within 30 minutes of bedtime, and with at least 7 hours remaining before planned awakening.

The Drug Enforcement Administration classified suvorexant as a Schedule IV controlled substance, effective January 2014, based on an eight-factor analysis that found the drug had low abuse potential relative to Schedule III substances but measurable reinforcing effects in recreational sedative users 2. This placed Belsomra in the same scheduling category as zolpidem (Ambien), eszopiclone (Lunesta), and the benzodiazepine class.

What the Belsomra Label Says: Key Warnings and Contraindications

The current Belsomra prescribing information carries several boxed and bolded warnings that reflect both pre-approval data and post-market experience 5.

CNS depressant effects and daytime impairment. The label warns that patients may experience next-day somnolence and instructs prescribers to use the lowest effective dose. The 20 mg dose carries a specific caution about impaired driving ability the morning after use.

Complex sleep behaviors. A label update added warnings about sleepwalking, sleep-driving, and other activities performed while not fully awake. The FDA required this language for all orexin receptor antagonists after post-market reports accumulated across the DORA class 6.

Narcolepsy-like symptoms. Because the orexin system is dysfunctional in narcolepsy type 1, blocking these receptors pharmacologically can produce symptoms resembling narcolepsy. The label notes that sleep paralysis, hypnagogic hallucinations, and cataplexy-like episodes have occurred in clinical trials and post-market reports.

Contraindication in narcolepsy. The only absolute contraindication is narcolepsy. Suvorexant should not be used in patients with this diagnosis 5.

Drug interactions. CYP3A4 inhibitors significantly increase suvorexant exposure. The label contraindicates concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, posaconazole, clarithromycin) and recommends dose reduction to 5 mg with moderate CYP3A4 inhibitors such as diltiazem and erythromycin.

Post-Market Safety Surveillance and Label Revisions

Between 2014 and 2019, the FDA's adverse event reporting system (FAERS) accumulated reports that led to two significant label revisions for Belsomra.

The first major change came in April 2019, when the FDA issued a safety communication requiring a boxed warning on all orexin receptor antagonists (including suvorexant, as well as the later-approved lemborexant) regarding complex sleep behaviors 6. The agency identified 66 cases of serious injuries and deaths linked to complex sleep behaviors across all insomnia medications, though the specific number attributed to suvorexant alone was not publicly broken out.

A FAERS database analysis published in 2020 examined 4,624 adverse event reports associated with suvorexant from August 2014 through June 2019 7. Somnolence, abnormal dreams, and sleep paralysis were among the most frequently reported events. The disproportionality analysis found a reporting odds ratio of 3.1 for sleep paralysis relative to other insomnia drugs, consistent with the orexin-blocking mechanism.

The FDA's Sentinel System, a distributed data network covering more than 100 million U.S. patients, has been used to monitor suvorexant prescribing patterns and outcomes in routine clinical practice. Sentinel analyses have shown that the majority of suvorexant prescriptions are written for the 10 mg dose, with step-ups to 15 mg or 20 mg occurring in roughly 20% of patients within the first 90 days 2.

Suvorexant in the Context of the DORA Class

Belsomra's approval opened the regulatory pathway for subsequent DORAs. Lemborexant (Dayvigo) received FDA approval in December 2019 8, and the European Medicines Agency approved daridorexant (Quviviq) in 2022. Each subsequent DORA benefited from the safety and efficacy precedent that suvorexant established.

Head-to-head data remain limited. One indirect treatment comparison published in the Journal of Clinical Sleep Medicine found no statistically significant differences in subjective sleep onset latency between suvorexant 20 mg and lemborexant 10 mg, though lemborexant showed a numerically shorter half-life (approximately 17.5 hours versus 12 hours for suvorexant) 8. Prescribers making formulary decisions often weigh this pharmacokinetic difference against individual patient factors like hepatic function and concomitant medications.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommended suvorexant for sleep maintenance insomnia, noting moderate-quality evidence from the key trials 9. The AASM did not recommend it for sleep onset insomnia alone, citing smaller effect sizes on that endpoint relative to other available agents. A 2023 update to the guideline revisited the entire DORA class and included lemborexant alongside suvorexant in its conditional recommendation for maintenance insomnia.

Patent Status, Generic Timeline, and Market Position

Merck's compound patent for suvorexant (U.S. Patent No. 8,329,738) was set to expire in 2029, with pediatric exclusivity potentially extending protection by six months. No generic suvorexant has received tentative FDA approval as of early 2026. Belsomra generated approximately $470 million in U.S. sales in 2022, though year-over-year revenue declined as lemborexant and daridorexant captured market share 2.

Cost remains a prescribing consideration. A 30-day supply of brand-name Belsomra typically ranges from $350 to $450 without insurance, and prior authorization requirements are common among commercial payers. Merck has maintained a patient assistance program that offers copay cards reducing out-of-pocket costs to as low as $15 per month for eligible commercially insured patients.

Belsomra holds the distinction of being the first approved drug in a mechanistic class that now includes three marketed agents across the U.S. and Europe. The regulatory scrutiny that narrowed its approved dose range from what Merck originally proposed set a precedent: the FDA has applied similarly conservative dose-ceiling logic to subsequent DORA approvals, weighing next-day impairment risk as a co-primary safety concern alongside traditional abuse liability assessments.

The recommended dose for most adults remains 10 mg nightly, increased to 20 mg if the lower dose is tolerated but insufficiently effective, taken with at least 7 hours of planned sleep time remaining 5.